Adenoma, advanced adenoma and colorectal cancer prevalence in asymptomatic 40‐ to 49‐year‐old subjects with a first‐degree family history of colorectal cancer

Blanco, Giovanna Del Vecchio; Cretella, M.; Paoluzi, Omero Alessandro; Caruso, Anna; Mannisi, E.; Servadei, Francesca; Romeo, S.; Grasso, E.; Sileri, Pierpaolo; Giannelli, M.; Biancone, Livia; Palmieri, G; Pallone, Francesco

doi:10.1111/codi.12263

Cited by 15 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The low prevalence of CRC cases (0.8%) found in our cohort complicated the estimation of the diagnostic performance of both markers to detect cancer. However, cancer prevalence of 0.65–0.7% has been described by others in familial-risk-screening scenarios ( Del Vecchio Blanco et al , 2013 ; Ng et al , 2013 ). This difficulty is frequently reported in high-risk cohorts evaluating performance of FIT, with no >6/595–20/1682 CRC cases detected ( Rozen et al , 2010 ; Castro et al , 2014 ).…”

Section: Discussionmentioning

confidence: 93%

Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test

et al. 2014

View full text Add to dashboard Cite

Background:The development of specific screening programs for individuals with a family history of colorectal cancer (CRC) is a priority. This study evaluates the diagnostic performance of serum soluble CD26 (sCD26) in family-risk individuals and compares this marker with the faecal immunochemical test for the detection of advanced neoplasia (AN) (CRC or advanced adenomas; AA).Methods:Five hundred and sixteen asymptomatic individuals with at least one first-degree relative with CRC were included. Serum sCD26 was measured in all the individuals who also underwent a colonoscopy (53 AA and four cancer cases were found) and a faecal immunochemical test.Results:Setting specificity to 90% and 95%, respectively, sCD26 showed a sensitivity of 39.6% and 28.3% for AA, and of 42.1% and 28.1% for AN. The combination of sCD26 and the faecal test detected AA and AN with a 52.8% and 56.1% sensitivity, corresponding to 93.5% specificity.Conclusions:The combination of serum sCD26 and the faecal blood test could result a valuable strategy for detecting AN in familial-risk CRC screening.

show abstract

Section: Discussionmentioning

confidence: 93%

Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test

et al. 2014

View full text Add to dashboard Cite

show abstract

“…One of the limitations of the study is the reduced number of CRC cases, though the 0.8% prevalence corresponds to that observed in other comparable screening cohorts [35][36][37]. A larger number of asymptomatic CRC cases from screening would be desirable not only to confirm the diagnostic capacity, but also to evaluate the performance for detecting distal and proximal tumors.…”

Section: Discussionmentioning

confidence: 88%

Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

Aberrant DNA methylation detected in liquid biopsies is a promising approach for colorectal cancer (CRC) detection, including premalignant advanced adenomas (AA). We evaluated the diagnostic capability of serum NEUROG1 methylation for the detection of AA and CRC. A CpG island in NEUROG1 promoter was assessed by bisulfite pyrosequencing in a case-control cohort to select optimal CpGs. Selected sites were evaluated through a nested methylation-specific qPCR custom assay in a screening cohort of 504 asymptomatic family-risk individuals. Individuals with no colorectal findings and benign pathologies showed low serum NEUROG1 methylation, similar to non-advanced adenomas. Contrarily, individuals bearing AA or CRC (advanced neoplasia—AN), exhibited increased NEUROG1 methylation. Using >1.3518% as NEUROG1 cut-off (90.60% specificity), 33.33% of AN and 32.08% of AA were identified, detecting 50% CRC cases. Nonetheless, the combination of NEUROG1 with fecal immunochemical test (FIT), together with age and gender through a multivariate logistic regression resulted in an AUC = 0.810 for AN, and 0.796 for AA, detecting all cancer cases and 35–47% AA (specificity 98–95%). The combination of NEUROG1 methylation with FIT, age and gender demonstrated a convenient performance for the detection of CRC and AA, providing a valuable tool for CRC screening programs in asymptomatic individuals.

show abstract

“…However, the measurement of serum NDKA levels in this group was conceived to verify the correct quantification of the molecule using the commercial ELISA assay, and to corroborate the difference in serum NDKA levels between healthy controls and CRC patients evidenced in our previous work by Western blot 29 . In the screening cohort, a small number of CRC patients were also found, corresponding to a prevalence of 0.78% which is expected in a familial-risk screening context (0.65–0.7%) 51 52 . Nevertheless, since the detection of AN is the goal of this type of approach, the total of 57 cases of CRC together with AA seem suitable for the analysis.…”

Section: Discussionmentioning

confidence: 95%

Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer

Otero-Estévez

Chiara

Barcia-Castro

et al. 2016

Sci Rep

View full text Add to dashboard Cite

We previously described the over-expression of nucleoside diphosphate kinase A (NDKA) in tumours and serum from colorectal cancer (CRC) patients, suggesting its use as biomarker. In this study we evaluated the diagnostic accuracy of serum NDKA to detect advanced neoplasia (CRC or advanced adenomas). Furthermore, the performance of NDKA was compared with the faecal immunochemical test (FIT). The study population included a case-control cohort and a screening cohort (511 asymptomatic first-degree relatives of CRC patients that underwent a colonoscopy and a FIT). Serum NDKA was elevated in CRC patients in the case-control cohort (p = 0.002). In the screening cohort, NDKA levels were higher for advanced adenomas (p = 0.010) and advanced neoplasia (p = 0.006) compared to no neoplasia. Moreover, elevated NDKA was associated with severe characteristics of adenomas (≥3 lesions, size ≥ 1 cm or villous component). Setting specificity to 85%, NDKA showed a sensitivity of 30.19% and 29.82% for advanced adenomas and advanced neoplasia, respectively. NDKA combined with FIT (100 ng/mL cut-off) detected advanced adenomas and advanced neoplasia with 45.28% and 49.12% sensitivity, with specificity close to 90%. The combination of serum NDKA and FIT can improve the detection of advanced neoplasia, mainly for lesions located on the proximal colon, in asymptomatic individuals with CRC family-risk.

show abstract

Adenoma, advanced adenoma and colorectal cancer prevalence in asymptomatic 40‐ to 49‐year‐old subjects with a first‐degree family history of colorectal cancer

Cited by 15 publications

References 38 publications

Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test

Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test

Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer

Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer

Contact Info

Product

Resources

About